Type II topoisomerase
From Wikipedia, the free encyclopedia
Type II topoisomerases cut both strands of the DNA helix simultaneously in order to change the linking number of the molecule.
Contents |
[edit] Function
Once cut, the ends of the DNA are separated, and a second DNA duplex is passed through the break. Following passage, the cut DNA is religated. This reaction allows type II topoisomerases to increase or decrease the linking number of a DNA loop by 2 units, and promotes chromosome disentanglement. Reactions involving the increase in supercoiling require two molecules of ATP. Janet Lindsley has done much work to examine how the hydrolysis of ATP translate to topo function. For example, DNA gyrase, a type II topoisomerase observed in E. coli and most other prokaryotes, introduces negative supercoils and decreases the linking number by 2. Gyrase also is able to remove knots from the bacterial chromosome. Along with gyrase, most prokaryotes also contain a second type IIA topoisomerase, termed topo IV. Gyrase and topo IV differ by their C-terminal domains which is believed to dictate substrate specificity and functionality for these two enzymes. Footprinting indicates that gyrase, which forms a 140 base-pair footprint, wraps DNA allowing it to introduce negative supercoils, while topo IV, which forms a 28 base-pair footprint, does not wrap DNA.
Eukaryotic type II topoisomerase cannot introduce supercoils; it can only relax them. This is thought to be unnecessary because the binding of DNA by histones increases potential superhelicity.
[edit] Topology simplification
Type IIA topoisomerases are essential in the separation of daughter strands at the end of replication. This function is performed by topo II in eukaryotes and by topo IV in prokaryotes. Failure to separate these strands leads to cell death. Type IIA topoisomerases have the special ability to relax DNA to a state below that of thermodynamic equilibrium, a feature unlike type IA, IIA, and IIB topoisomerases. This ability, known as topology simplification, was first identified by Rybenkov et al (Science 1997). The hydrolysis of ATP drives this simplification, but a clear molecular mechanims for this simplification is still lacking. Several models to explain this phenomenon have been proposed, including two models that rely on the ability of type IIA topoisomerases to recognize bent DNA duplexes (Vologodskii, Proceedings of the National Academy of Science 1999). Biochemistry, electron microscopy, and the recent structure of topo II bound to DNA reveals that type IIA topoisomerases bind at the apices of DNA.
[edit] Classification
There are two subclasses of type II topoisomerases, type IIA and IIB.
- Type IIA topoisomerases include the enzymes DNA gyrase, eukaryotic topoisomerase II, and bacterial topoisomerase IV.
- Type IIB topoisomerases are structurally and biochemically distinct, and comprise a single family member, topoisomerase VI. Type IIB topoisomerases are found in archaea and some higher plants.
In cancers, the topoisomerase IIalpha is highly expressed in highly proliferating cells. In certain cancers, such as peripheral nerve sheath tumors, high expression of its encoded protein is also associated to poor patient survival.
Type IIA topoisomerases form double-stranded breaks with four-base pair overhangs, while type IIB topoisomerases form double-stranded breaks with two base overhangs (Buhler, Lebbink, Bocs, Ladenstein, and Forterre, Journal of Biological Chemistry 2001).
[edit] Structure of type IIA topoisomerases
Type IIA topoisomerases consist of several key motifs: an N-terminal GHKL ATPase domain (for Gyrase, Hsp, Kinase and MutL), a Toprim domain (sometimes called a Rossman fold) which exists both in Type II topoisomerases, type IA topoisomerases, and bacterial primase (DnaG),a central DNA-binding core (which structurally forms a heart shaped structure), and a variable C-terminal domain.
Eukaryotic type II topoisomerases are homodimers (A2), while prokaryotic type IIs are heterodimers (A2B2). Prokaryotes hae the ATPase domain and the Toprim fold on one polypeptide, while the DNA cleavage core and the CTD lies on a second polypeptide. For gyrase, the first polypeptide is called GyrB and the second polypeptide is called GyrA. For topo IV, the first polypeptide is called ParE and the second polypeptide is called ParC.
The structure of the N-terminal ATPase domain of gyrase (Wigley, Davies, Dodson, Maxwell, and Dodson, Nature 1991) and yeast topo II (Classen and Berger, Proceedings of the National Academy of Science, 2003, PDB ID=1PVG) have been solved in complex with AMPPNP (an ATP analogue). Showing that two ATPase domains dimerize to form a closed conformation. For gyrase, the structure has a substantial hole in the middle, presumably to capture the T-segment.
Linking the ATPase domain to the Toprim fold is a helical element known as the transducer domain. This domain is thought to communicate the nucleotide state of the ATPase domain to the rest of the protein. Modifications to this domain effects topoisomerase activity, and structural work done by the Verdine group shows that the ATP state effects the orientation of the transducer domain (Journal of Biological Chemistry, 2006).
The central core of the protein contains a Toprim fold and a DNA binding core that contains a Winged Helix domain (WHD), often referred to as a CAP domain since it was first identified to resemble the WHD of Catabolite Activator Protein. The catalytic tyrosine lies on this WHD. The Toprim fold is a Rossman fold that contains three invarient acidic residues that coordinate a magnesium ion that is involved in DNA cleavage and DNA religation (Avarind, Leipe, Konin, Nucleic Acids Research 1998). The structure of the Toprim fold and DNA binding core of yeast topo II was first solved by Berger and Wang (Nature 1996, PDB ID = 1BGW) and the first gyrase DNA binding core was solved by Morais Cabral et al (Nature 1997, PDB ID = 1AB4). The structure solved by Berger revealed important insights into the function of the enzyme. The DNA binding core consists of the WHD which leads to a tower domain. A coiled-coil region leads to a C-terminal domain that forms the main dimer interface for this crystal state (often termed the C-gate). Interestingly, while the original topo II structure shows a situation where the WHDs are separated by a large distance, the structure of gyrase shows a closed conformation, where the WHD close.
The topo II core was later solved in two new conformations, one by Fass et. al. (Nature Structure Biology 1999, PDB ID = 1BJT) and one by Dong et. al. (Nature 2007, PDB ID = 2RGR). The Fass structure shows that the Toprim domain is flexible and that this flexibility can allow the Toprim domain to coordinate with the WHD to form a competent cleavage complex. This was eventually substantiated by the Dong et. al. structure that was solved in the presence of DNA. This last structure showed that the Toprim domain and the WHD formed a cleavage complex very similar to that of the type IA topoisomerases, indicated how DNA binding and cleavage could be uncoupled, and the structure showed that DNA was bent by ~ 150 degrees through an invariant isoleucine (in topo II it is I833 and in gyrase it is I172). This mechanism of bending resembles closely that of Integration Host Factor and HU, two architectural proteins in bacteria. In addition, while the previous structures of the DNA binding core had the C-gate closed, this structure captured the gate open, a key step in the two gate mechanism (see below).
The C-terminal region of the prokayrotic topoisomerases have been solved in multiple species. The first structure of a C-terminal domain of gyrase was solved by Corbett et. al. (Proceedings of the National Academy of Science, 2004, PDB ID = 1SUU) and the C-terminal domain of topo IV was solved by Corbett et. al. (Journal of Molecular Biolgy, 2006, PDB ID = 1zvt and 1zvu). The structures formed a novel beta barrel which bends DNA by wrapping the nucleic acid around itself. The bending of DNA by gyrase has been proposed as a key mechanism in the ability of gyrase to introduce negative supercoils into the DNA. Unlike the C-terminal domain of prokaryotic topoisomerases, the function of the C-terminal domain of eukaryotic topoisomerase II is still not clear.
[edit] Structures of type IIB topoisomerases
The organization of type IIB topoisomerases are similar to that of type IIAs, except that all type IIBs have two genes and form heterodimers. On one gene, termed topo VI-B (since it resembles gyrB), contains the ATPase domain, a H2TH domain, and the transducer domain. The second gene, termed topo VI-A, contains the WHD and the Toprim domain.
The ATPase domain of topo VI B was solved in multiple nucleotide states (Corbett and Berger, EMBO J 2003). It closely resembles that of the GHKL domain of topo II and MutL and shows that the nucleotide state (ADP versus ATP) effects the orientation of the transducer domain (pdb ID= 1MU5 and 1MX0).
The structure of topo VI-A was solved by Bergerat et. al. (Nature 1997), showing that the HTH and Toprim fold had a novel conformation compared with that of topo IIA.
A recent structure of the topo VI A/B complex was solved, showing an open and closed conformation, two states that are predicted in the two-gate mechanism (see below). These structures, of which one is a X-ray crystal structure and the other is a Small Angle X-ray Scattering (SAXS) reconstruction shows that the ATPase domain can either be open or closed (Corbett, Benedetti, Berger Nature Structure Molecular Biology, 2007, PDB ID = 2Q2E).
[edit] Mechanism of type II topoisomerases
Type IIA topoisomerase operates through a "two-gate" mechanism, a mechanism supported by biochemistry (Roca and Wang) as well as by structural work (Berger and Wang).
A strand of DNA, called the Gated-segment, or G-segment is bound by a central DNA-binding gate (DNA-gate). A second strand of DNA, called the Transport-segment (sometimes called the transfer), or T-segment is captured by the dimerization of the N-terminal ATPase domain (the ATPase-gate) as two molecules of ATP are bound. Hydrolysis of ATP and release of a inorganic phosphate leads to the cleavage of the G-segment, as the catalytic tyrosines form a covalent phosphotyrosine bond with the 5' end of the DNA. This creates a four-base overhang and a double stranded break in the G-segment. As the DNA-binding gate separates, the T-segment is transfered through the G-segment. The G-segment is sealed, leading to the C-terminal gate (or C-gate) to open, allowing for the release of the T-segment. Release of product ADP leads to a reset of the system, and allows a second T-segment to be captured.
Type IIB topoisomerases operate through a similar fashion, except that the protein forms a two-base overhang in the G-segment and that the C-terminal gate is completely missing.
[edit] Catenation
Catenation is where two circular DNA strands are linked together like chain links. This occurs after DNA replication where two single strands are catenated can still replicate but cannot separate into the two daughter cells. As Type II topoisomerses break a double strand they can fix this state (Type I topoisomerases could only do this if there was already a single strand nick) and the correct chromosome number can remain in daughter cells. As linear DNA in eukaryotes is so long they can be thought of as being without ends and Type II topoisomerases are needed for the same reason.
[edit] Inhibition
Small molecules that target type II topoisomerase are divided into two classes: inhibitors and poisons. Inhibitors of type II topoisomerase include ICRF-187, ICRF-193, and mitindomide. These molecules work by inhibiting the ATPase activity, specifically by acting as a un-competative inhibitor of ATP. This has been shown through structural studies (Classen et. al. Proceedings of the National Academy of Science, 2005) and biochemical studies performed by the Lindsley group. Poisons of type II topoisomerases include etoposide, Novobiocin and teniposide. These small molecules target the DNA-protein complex. Some of these molecules lead to increased cleavage, while others, such as etoposide, inhibit religation.
The experimental anti-tumor drug m-AMSA (4'-(9'-acridinylamino)methanesulfon-m-anisidide) also inhibits type 2 topoisomerase.[1]
[edit] References
- ^ Willmore E, de Caux S, Sunter NJ, et al (2004). "A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia". Blood 103 (12): 4659–65. doi:. PMID 15010369.
[edit] External links
|
|||||
